- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
-
Barberio B, Savarino EV, Card T, Canova C, Baldisser F, Gubbiotti A, Massimi D, Ghisa M, Zingone F
- KMID: 2525078
- Intest Res.
- 2022 Jan;20(1):114-123.
- doi: 10.5217/ir.2021.00037
Background/Aims: Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a... -
- CITED
-
- Close
- SHARE
-
- Close
- The Lyon Consensus: Does It Differ From the Previous Ones?
-
Ghisa M, Barberio B, Savarino V, Marabotto E, Ribolsi M, Bodini G, Zingone F, Frazzoni M, Savarino E
- KMID: 2503999
- J Neurogastroenterol Motil.
- 2020 Jul;26(3):311-321.
- doi: 10.5056/jnm20046
Gastroesophageal reflux disease (GERD) is a complex disorder with heterogeneous symptoms and a multifaceted pathogenetic basis, which prevent a simple diagnostic algorithm or any categorical classification. Clinical history, questionnaires and... -
- CITED
-
- Close
- SHARE
-
- Close
